The $2 peak was when they first tried to commercialise Colostat....

The $2 peak was when they first tried to commercialise Colostat. The clinical trial results were amazing, it looked good! They applied for TGA approval, but withdrew the application because the kit manufacturing process (French company) wasn’t refined enough. Now they have a new vastly more experienced CEO and a new American manufacturer. A lot of work has been done. The commercial pathway later this year will be the well trodden ‘lab developed test’, not via TGA at first…

I get the sense the share price is it’s suffering from ‘once bitten twice shy’